Heron Therapeutics Inc (STU:AXD2)
€ 1.728 0.056 (3.35%) Market Cap: 266.05 Mil Enterprise Value: 366.24 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 06:35PM GMT
Release Date Price: €16.09 (+4.20%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good morning. Thanks for joining us at the Bank of America Merrill Lynch conference. I am Tazeen Ahmad, I'm the Senior SMid Biotech Analyst here. It's my pleasure to introduce the next company. From Heron, standing right next to me is CEO, Barry Quart. He's going to give you an introduction to the company, go through some slides and then afterwards if you have any questions feel free to pop them over to us. Thanks. I'll turn it over to Barry.

Barry D. Quart
Heron Therapeutics, Inc. - President, CEO & Director

Thanks, Tazeen. Great pleasure to be here. I'm going to try to use this time for a quick update. We'll start with the obvious forward-looking statements. And this is a quick 10,000-foot overview of Heron. For people who are not familiar with the company, we have 2 commercial products both in the CINV space. And then our lead program in postoperative pain, HTX-011, we unfortunately received a CRL from the FDA on April 30. And so probably the best thing to do is to go right into that.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot